Scope
NICE guideline NG196 covers the detection, diagnosis and management of atrial fibrillation (AF). Its recommendations are dated 2006 to 2021. The guideline sets out a two-step diagnostic approach and indications for echocardiography. It uses CHA2DS2-VASc for stroke risk and ORBIT for bleeding risk. It covers anticoagulant choice, monitoring and review, and stopping anticoagulation. Other sections address rate and rhythm control, cardioversion, ablation, acute presentation, and prevention and management of postoperative AF. Shared decision-making is emphasised throughout.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Detection, diagnosis and cardiac assessment
- When AF is suspected, palpate the pulse manually. This includes people presenting with any of the following: - breathlessness - palpitations - syncope or dizziness - chest discomfort - stroke or TIA If the pulse is irregular, confirm the diagnosis with a 12-lead ECG, whether or not symptoms are present. [1]
- Some people have suspected paroxysmal AF that a 12-lead ECG has not captured. Use a 24-hour ambulatory monitor if asymptomatic episodes are suspected or symptomatic episodes are less than 24 hours apart. If symptomatic episodes are more than 24 hours apart, use an ambulatory monitor, event recorder or other ECG technology for a period suited to detection. [1]
- Perform transthoracic echocardiography in people with AF in four situations: - when a baseline study matters for long-term management - when rhythm control including cardioversion is being considered - when structural or functional heart disease is suspected or high risk and would influence management - when clinical risk stratification for antithrombotic therapy needs refinement Do not routinely perform it solely to refine stroke risk once anticoagulation has already been agreed on clinical criteria. [1]
Stroke and bleeding risk assessment
- Assess stroke risk with CHA2DS2-VASc in the following groups: - paroxysmal, persistent or permanent AF, whether symptomatic or not - atrial flutter - people with a continuing risk of recurrence after cardioversion or catheter ablation [1]
- Assess bleeding risk when considering starting anticoagulation and when reviewing people already taking it. Use the ORBIT score, chosen for its higher accuracy in predicting absolute bleeding risk. Other tools may need to be used until ORBIT is embedded in clinical pathways and electronic systems. [1]
- Offer monitoring and support to modify bleeding risk factors. These include: - uncontrolled hypertension - poor INR control on vitamin K antagonists - concurrent antiplatelets, SSRIs or NSAIDs - harmful alcohol consumption - reversible causes of anaemia [1]
Stroke prevention and anticoagulation
- Offer a DOAC to people with AF and a CHA2DS2-VASc score of 2 or above. Consider a DOAC for men with a score of 1. In both cases, take bleeding risk into account. Apixaban, dabigatran, edoxaban and rivaroxaban are options when used within NICE technology appraisal criteria. [1]
- When choosing an anticoagulant, check each drug's contraindications and follow BNF and MHRA advice, particularly on renal dosing, reversal agents and monitoring. Use clinical risk profiles and personal preferences to guide the choice. Discuss with the person that for most people the benefit of anticoagulation outweighs the bleeding risk. For those at increased bleeding risk the benefit may not always outweigh it, so careful monitoring of bleeding risk is important. [1]
- Offer a vitamin K antagonist if DOACs are contraindicated, not tolerated or unsuitable. Adults who are stable on a vitamin K antagonist should continue it. Discuss switching at their next routine appointment, taking their time in therapeutic range into account. [1]
- Do not offer anticoagulation to people under 65 years whose only risk factor is their sex, that is, a CHA2DS2-VASc score of 0 in men or 1 in women. Do not withhold anticoagulation solely because of age or falls risk. [1]
- For people on a vitamin K antagonist, calculate time in therapeutic range (TTR) at each visit using a validated method. Exclude the first 6 weeks of treatment and calculate over a maintenance period of at least 6 months. Reassess anticoagulation if any of the following apply within the past 6 months: - 2 INR values above 5, or 1 above 8 - 2 INR values below 1.5 Also reassess if TTR is below 65%. [1]
- Do not use aspirin monotherapy solely for stroke prevention. Consider left atrial appendage occlusion, after discussing its benefits and risks, only when anticoagulation is contraindicated or not tolerated. Do not offer it otherwise as an alternative to anticoagulation. [1]
- For people not taking an anticoagulant, review stroke risk on reaching age 65. Also review it at any age if they develop any of the following: - diabetes - heart failure - peripheral arterial disease - coronary heart disease - stroke, TIA or systemic thromboembolism [1]
- Further review depends on anticoagulation status: - Not anticoagulated because of bleeding risk or other factors: review stroke and bleeding risk annually and document all reviews and decisions. - Anticoagulated: review the need for and quality of anticoagulation at least annually, or sooner after relevant events. Take into account MHRA advice on DOACs about bleeding risk and the need to monitor renal function in renal impairment. [1]
- Do not stop anticoagulation merely because AF is no longer detectable. Base any decision to stop on reassessed stroke and bleeding risk using CHA2DS2-VASc and ORBIT, together with the person's preferences. [1]
Rate and rhythm control (non-acute)
- Offer rate control as the first-line strategy, except in the following situations: - AF has a reversible cause - heart failure is thought to be primarily due to AF - AF is new onset - atrial flutter is suitable for ablation - clinical judgement favours rhythm control [1]
- For initial rate-control monotherapy, offer a standard beta-blocker (not sotalol), diltiazem or verapamil. The exception is people with the features described in recommendation 1.7.4, which sets out the criteria for digoxin monotherapy. Choose according to symptoms, heart rate, comorbidities and preferences. Diltiazem use was off-label in April 2021. In people with concomitant heart failure, follow chronic heart failure guidance on using beta-blockers and avoiding calcium-channel blockers. [1]
- Consider digoxin monotherapy for non-paroxysmal AF in two situations: the person does little or no exercise, or other rate-limiting drugs are ruled out by comorbidities or preference. If monotherapy fails and ongoing symptoms reflect poor ventricular rate control, consider combining any 2 of a beta-blocker, diltiazem or digoxin. Diltiazem use in this way was off-label in April 2021. Do not use amiodarone for long-term rate control. [1]
- Consider pharmacological and/or electrical rhythm control if symptoms persist despite rate control, or if rate control has failed. If long-term drug rhythm control is needed, consider a standard beta-blocker first unless contraindicated. Avoid class 1c agents such as flecainide or propafenone in known ischaemic or structural heart disease. Consider amiodarone for left ventricular impairment or heart failure. [1]
- When cardioverting AF that has lasted longer than 48 hours, offer electrical rather than pharmacological cardioversion. Consider amiodarone from 4 weeks before until up to 12 months after electrical cardioversion to maintain sinus rhythm, after discussing its benefits and risks. [1]
- Ablation applies to symptomatic paroxysmal or persistent AF where drugs are unsuccessful, unsuitable or not tolerated. Consider radiofrequency point-by-point ablation first, or cryoballoon or laser balloon ablation if that is unsuitable. Explain that ablation is not always effective and that symptom relief may not last. Consider antiarrhythmic drugs for 3 months afterwards to prevent recurrence, weighing preferences, risks and benefits, and reassess the need at 3 months. [1]
Acute presentation
- Perform emergency electrical cardioversion, without waiting for anticoagulation, when new-onset AF causes life-threatening haemodynamic instability. Without such instability, offer rate or rhythm control if onset was less than 48 hours ago. Offer rate control if onset was more than 48 hours ago or is uncertain. [1]
- If acute decompensated heart failure is suspected, seek senior specialist advice on beta-blockers and do not use calcium-channel blockers. When pharmacological cardioversion of new-onset AF is agreed: - offer flecainide or amiodarone if there is no structural or ischaemic heart disease - offer amiodarone if structural heart disease is present - do not use magnesium or calcium-channel blockers [1]
- In new-onset AF with no or subtherapeutic anticoagulation, offer heparin at presentation unless contraindicated. Continue heparin until full assessment is complete and risk-based antithrombotic therapy has started. If AF has lasted more than 48 hours or for an uncertain time and long-term rhythm control is planned, delay cardioversion until the person has had at least 3 weeks of therapeutic anticoagulation, using rate control meanwhile as appropriate. [1]
Postoperative atrial fibrillation
- For people having cardiothoracic surgery, reduce postoperative AF risk by offering one of three options: - amiodarone - a standard beta-blocker other than sotalol - a rate-limiting calcium-channel blocker (diltiazem or verapamil) Do not offer digoxin. Diltiazem use was off-label in April 2021. [1]
- In cardiothoracic surgery, continue existing beta-blockers unless contraindications such as postoperative bradycardia or hypotension develop. Do not start statins solely to prevent postoperative AF, but continue statins in people already taking them. [1]
- For new-onset AF after cardiothoracic surgery, consider either rhythm or rate control. If rhythm control is chosen, reassess the need for antiarrhythmic drugs at a suitable point, usually around 6 weeks. Manage AF after non-cardiothoracic surgery like new-onset AF of any other cause. In all cases, use appropriate antithrombotic therapy and correct identifiable causes such as electrolyte imbalance or hypoxia. [1]
Limitations and use
- This summary is based on the clinical recommendations only. Research recommendations, rationale/impact, update-history and committee chapters were excluded from the source, and flowcharts were available only as alternative text.
- Initial management of stroke with AF is deferred to NICE's stroke and TIA guideline (recommendation 1.4.17 there). Antiplatelet therapy after myocardial infarction in anticoagulated people is deferred to the acute coronary syndromes guideline.
- Detailed DOAC eligibility criteria sit in the cited NICE technology appraisals (TA355, TA275, TA256, TA249). Dronedarone use is referenced to TA197, and VKA self-monitoring and left atrial appendage occlusion procedures to separate HealthTech guidance. These documents were not supplied.
- Some recommendations are not detailed in this summary. These include TOE indications and TOE-guided cardioversion, pill-in-the-pocket criteria, the pace-and-ablate strategy, surgical ablation, referral timing and the personalised package of care.
- The bracketed years attached to recommendations (2006 to 2021, for example '2006, amended 2014') show when each recommendation was issued or amended. Several recommendations rely on linked NICE guidelines (heart failure, hypertension, shared decision making, medicines optimisation) for operational detail.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Atrial fibrillation: diagnosis and management
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 27 April 2021
- Publisher’s latest update
- 30 June 2021
- Resource type
- Clinical guideline · House clinical summary
Earlier House summaries: atrial fibrillation nice
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.